BARALDI, CARLO
 Distribuzione geografica
Continente #
EU - Europa 9.149
NA - Nord America 6.355
AS - Asia 2.630
SA - Sud America 448
Continente sconosciuto - Info sul continente non disponibili 148
AF - Africa 68
OC - Oceania 36
Totale 18.834
Nazione #
IT - Italia 6.650
US - Stati Uniti d'America 6.164
GB - Regno Unito 1.020
SG - Singapore 827
CN - Cina 570
BR - Brasile 334
VN - Vietnam 317
HK - Hong Kong 313
FR - Francia 274
SE - Svezia 194
DE - Germania 187
NL - Olanda 180
RU - Federazione Russa 127
BD - Bangladesh 103
CA - Canada 94
IN - India 83
CH - Svizzera 74
KR - Corea 74
UA - Ucraina 71
FI - Finlandia 68
TR - Turchia 64
ID - Indonesia 59
MX - Messico 54
ES - Italia 51
JP - Giappone 47
AR - Argentina 43
PL - Polonia 42
BG - Bulgaria 40
IE - Irlanda 37
AU - Australia 34
ZA - Sudafrica 21
AE - Emirati Arabi Uniti 19
EC - Ecuador 19
IQ - Iraq 19
CO - Colombia 17
EG - Egitto 17
IR - Iran 17
BE - Belgio 16
PK - Pakistan 16
TW - Taiwan 16
AT - Austria 15
PH - Filippine 15
CR - Costa Rica 13
MY - Malesia 11
NO - Norvegia 11
DK - Danimarca 10
CZ - Repubblica Ceca 9
HU - Ungheria 9
LT - Lituania 9
CL - Cile 8
GR - Grecia 8
NP - Nepal 8
AL - Albania 7
IL - Israele 7
JO - Giordania 7
PT - Portogallo 7
DZ - Algeria 6
JM - Giamaica 6
PE - Perù 6
PY - Paraguay 6
TN - Tunisia 6
UY - Uruguay 6
BY - Bielorussia 5
KG - Kirghizistan 5
MA - Marocco 5
SA - Arabia Saudita 5
UZ - Uzbekistan 5
VE - Venezuela 5
DO - Repubblica Dominicana 4
EE - Estonia 4
ET - Etiopia 4
GT - Guatemala 4
KE - Kenya 4
RS - Serbia 4
EU - Europa 3
GE - Georgia 3
HR - Croazia 3
KZ - Kazakistan 3
MD - Moldavia 3
PR - Porto Rico 3
SK - Slovacchia (Repubblica Slovacca) 3
TH - Thailandia 3
AM - Armenia 2
CU - Cuba 2
GY - Guiana 2
KH - Cambogia 2
LB - Libano 2
MT - Malta 2
NI - Nicaragua 2
NZ - Nuova Zelanda 2
OM - Oman 2
SC - Seychelles 2
SI - Slovenia 2
SV - El Salvador 2
A1 - Anonimo 1
A2 - ???statistics.table.value.countryCode.A2??? 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BO - Bolivia 1
Totale 18.670
Città #
Ashburn 835
Southend 725
Milan 613
Singapore 515
Fairfield 507
Santa Clara 503
Rome 408
San Jose 330
Chandler 315
Hong Kong 302
Woodbridge 253
Houston 215
Seattle 215
Council Bluffs 188
Cambridge 178
Wilmington 164
Naples 151
Modena 144
Hefei 126
London 125
Beijing 121
Nyköping 119
Turin 119
New York 109
Bologna 103
Ho Chi Minh City 102
Los Angeles 100
Florence 95
Ann Arbor 86
Dearborn 82
The Dalles 82
Chicago 79
Hanoi 73
Seoul 59
Catania 58
Genoa 57
Palermo 55
Jacksonville 53
Bari 51
Helsinki 50
Lauterbourg 48
Verona 48
Jakarta 47
Parma 46
São Paulo 44
Dallas 43
Moscow 42
San Diego 42
Pescara 39
Shanghai 36
Cagliari 35
Princeton 33
Boston 32
Sofia 31
Orem 29
Buffalo 28
Salt Lake City 28
Toronto 28
Zurich 28
Mexico City 26
Redwood City 25
Tokyo 25
Atlanta 24
Phoenix 24
Como 23
Munich 23
Warsaw 23
Brescia 22
Amsterdam 21
Eugene 21
Frankfurt am Main 20
L’Aquila 20
Dublin 19
Elk Grove Village 19
Fremont 19
Chennai 18
Columbus 18
Messina 18
Paris 18
Tampa 18
Brooklyn 17
Monza 17
Padova 17
Philadelphia 17
Reggio Emilia 17
Ventimiglia 17
Bergamo 16
Dalmine 16
Montreal 16
Perugia 16
Brasília 15
Bremen 15
Da Nang 15
Haiphong 15
Manchester 15
Anápolis 14
Düsseldorf 14
Lucca 14
Trento 14
Washington 14
Totale 9.927
Nome #
Correlazione tra fumo di cannabis e pneumotorace spontaneo. 6.993
Allopregnanolone serum levels in female migraineurs 923
Seizures of illicit substances for personal use in two Italian provinces: analysis of trends by type and purity from 2008 to 2017 684
Development and validation of a liquid chromatography-tandem mass spectrometric assay for quantitative analyses of triptans in hair 528
Hair analysis for detection of triptans occasionally used or overused by migraine patients-a pilot study 439
Hair testing in clinical setting: simultaneous determination of 50 psychoactive drugs and metabolites in headache patients by LC tandem MS 412
Monitoring of adherence to headache treatments by means of hair analysis 412
Medication overuse and chronic migraine: a critical review according to clinical pharmacology 408
Comparison of pregnenolone sulfate, pregnanolone and estradiol levels between patients with menstrually-related migraine and controls: an exploratory study 375
Diagnostic accuracy of hair analysis for the detection of triptan overuse in migraineurs 364
A case-control study of visually evoked postural responses in childhood with primary headaches 329
Secondary spontaneous pneumothorax and bullous lung disease in cannabis and tobacco smokers. A case-control study. 323
Exploration of candidate serum biomarkers potentially related to the chronic pain condition in Medication-overuse headache 318
Serum changes of apolipoproteins in Medication Overuse Headache (MOH) 311
Serum levels of allopregnanolone, progesterone and testosterone in menstrually-related and postmenopausal migraine: A cross-sectional study 311
Erenumab per il trattamento preventivo dell'emicrania cronica: efficacia e sicurezza fino a un anno, predittori di risposta ed effetti della sospensione. 300
Intrapatient variability of the hair levels of pain medications in chronic migraine patients - a pilot study 295
Anti-CGRP monoclonal antibodies improve cognitive function in patients affected by chronic migraine complicated with medication overuse-headache 294
Melanocortin receptor agonist NDP-α-MSH improves cognitive deficits and microgliosis but not amyloidosis in advanced stages of AD progression in 5XFAD and 3xTg mice 282
Proteomic serum profile of female migraineurs 281
Polypharmacy Among Headache Patients: A Cross-Sectional Study 280
Hair testing as a marker of adherence to headache treatments 276
Glutamate receptor antagonists with the potential for migraine treatment 274
Oral Cannabinoid Preparations for the Treatment of Chronic Migraine: A Retrospective Study 273
Proteomic serum profile in menstrual-related and post menopause migraine 263
Targeting pituitary adenylate cyclase-activating polypeptide (PACAP) with monoclonal antibodies in migraine prevention: a brief review 254
Easy tools to screen Italian women suffering from migraine with and without aura in early reproductive age 242
Erenumab for the preventive treatment of chronic migraine complicated with medication overuse headache: an observational, retrospective, 12-month real-life study 225
Chronic migraine evolution after 3 months from erenumab suspension: real-world-evidence-life data 206
Chronic Migraine and Medication Overuse Headache Worsening After OnabotulinumtoxinA Withdrawn Due to the Severe Acute Respiratory Syndrome-Coronavirus-2 Pandemic 200
Occlusal splint therapy in patients with Ménière’s disease and temporomandibular joint disorder 200
Visually Evoked Postural Responses (VEPRs) in Children with Vestibular Migraine 195
Topical Cannabidiol in the Treatment of digital ulcers in patients with Scleroderma: comparative Analysis and Literature Review 184
OnabotulinumtoxinA: Still the Present for Chronic Migraine 174
Galcanezumab for the treatment of chronic migraine and medication overuse headache: Real-world clinical evidence in a severely impaired patient population 165
SAT0285 EVALUATION OF CHRONIC PAIN IN PATIENTS WITH SYSTEMIC SCLEROSIS COMPARED TO THOSE WITH CHRONIC HEADACHE AND RHEUMATOID ARTHRITIS 162
Identification of candidate proteomic markers in the serum of medication overuse headache patients: An exploratory study 160
Monoclonal anti-CGRP antibodies in post-menopausal women: a real-life study 154
Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen study 131
Correction to: Monoclonal anti‑CGRP antibodies in post‑menopausal women: a real‑life study (Acta Neurologica Belgica, (2023), 123, 3, (1039-1047), 10.1007/s13760-023-02190-5) 118
Evaluation of the risk of hypertension in patients treated with anti-CGRP monoclonal antibodies in a real-life study 116
Totale 18.834
Categoria #
all - tutte 52.767
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 52.767


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.066 0 0 0 138 48 79 64 116 127 117 220 157
2022/20232.537 166 191 187 224 189 230 188 229 305 139 252 237
2023/20242.547 212 213 227 207 265 193 238 221 160 185 225 201
2024/20253.140 178 151 145 267 432 385 259 206 333 195 279 310
2025/20264.174 332 170 260 540 751 247 506 196 362 369 228 213
2026/20271.138 288 263 253 334 0 0 0 0 0 0 0 0
Totale 18.834